5-Amino 1MQ — 50mg

5-Amino-1-methylquinolinium (5-Amino 1MQ) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), a metabolic enzyme that consumes S-adenosylmethionine (SAM) to methylate nicotinamide — simultaneously depleting two critical cellular resources: the universal methyl donor (SAM) and the NAD⁺ salvage precursor (nicotinamide). NNMT is normally expressed at low levels in most tissues, but elevated NNMT activity in adipose tissue, muscle, and liver has emerged over the past decade as a consistent molecular signature of obesity, insulin resistance, and age-related metabolic decline.

By inhibiting NNMT, 5-Amino 1MQ restores intracellular NAD⁺ and SAM pools, which drives several downstream metabolic consequences: increased histone methylation (gene expression remodeling), improved mitochondrial biogenesis and fatty acid oxidation, and shifted adipocyte phenotype toward thermogenic metabolism. In rodent models of diet-induced obesity, oral 5-Amino 1MQ produced significant reductions in body weight and adipose mass, reduced lipid accumulation in liver, and improved insulin sensitivity — all without caloric restriction or exercise intervention. These outcomes have positioned the compound as a candidate exercise- and restriction-independent metabolic modulator.

Unlike GLP-1 class agents that act centrally to reduce caloric intake, 5-Amino 1MQ works through peripheral metabolic rewiring — making it mechanistically complementary rather than redundant to appetite-suppressing agents. This distinct mechanism has generated interest in its potential as a research companion compound to GLP-1 investigations, in age-related sarcopenic obesity models, and in fatty liver disease research where hepatic NAD⁺ restoration is mechanistically relevant. The compound is technically a small molecule rather than a peptide but is frequently grouped with metabolic research peptides due to its shared research context and delivery format.